Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EPS (Weighted Average and Diluted) (2016 - 2026)

Pharma-Bio Serv's EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at $0.0 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 168.99% year-over-year to $0.0; the TTM value through Jan 2026 reached $0.01, up 109.38%, while the annual FY2025 figure was -$0.0, 88.24% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.0 in Q1 2026 per PBSV's latest filing, up from -$0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.02 in Q3 2023 to a low of -$0.07 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.0, with a median of $0.01 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 3265.68% in 2024, then soared 168.99% in 2026.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.01 in 2022, then crashed by 127.23% to -$0.0 in 2023, then tumbled by 3265.68% to -$0.07 in 2024, then surged by 88.41% to -$0.01 in 2025, then surged by 112.5% to $0.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's EPS (Weighted Average and Diluted) are $0.0 (Q1 2026), -$0.01 (Q4 2025), and $0.01 (Q3 2025).